HilleVax (NASDAQ:HLVX) Earns “Neutral” Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of HilleVax (NASDAQ:HLVX) in a research report sent to investors on Monday morning,Benzinga reports. HC Wainwright currently has a $2.00 target price on the stock.

HilleVax Stock Performance

Shares of HLVX opened at $1.50 on Monday. HilleVax has a 52 week low of $1.37 and a 52 week high of $16.31. The stock has a market capitalization of $74.71 million, a price-to-earnings ratio of -0.48 and a beta of 0.76. The stock has a fifty day moving average of $1.79 and a 200-day moving average of $1.86.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). As a group, equities analysts forecast that HilleVax will post -2.64 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Intech Investment Management LLC bought a new stake in HilleVax in the fourth quarter valued at approximately $26,000. SG Americas Securities LLC lifted its stake in shares of HilleVax by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock valued at $38,000 after purchasing an additional 6,916 shares during the period. Ieq Capital LLC boosted its stake in HilleVax by 71.1% during the fourth quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock worth $47,000 after acquiring an additional 9,344 shares in the last quarter. Bank of Montreal Can increased its stake in HilleVax by 47.1% in the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company’s stock valued at $74,000 after purchasing an additional 11,459 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in HilleVax by 328.0% in the fourth quarter. Russell Investments Group Ltd. now owns 38,236 shares of the company’s stock valued at $79,000 after acquiring an additional 29,303 shares during the period. 86.42% of the stock is owned by institutional investors and hedge funds.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.